BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12005203)

  • 41. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
    Herbert JM; Bernat A; Samama M; Maffrand JP
    Thromb Haemost; 1996 Jul; 76(1):94-8. PubMed ID: 8819259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term treatment with nitrate is not sufficient to induce in vivo antithrombotic effects in rats and mice.
    Kramkowski K; Leszczynska A; Przyborowski K; Proniewski B; Marcinczyk N; Rykaczewska U; Jarmoc D; Chabielska E; Chlopicki S
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):85-94. PubMed ID: 27743016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress.
    Uemura T; Kawasaki T; Taniguchi M; Moritani Y; Hayashi K; Saito T; Takasaki J; Uchida W; Miyata K
    Br J Pharmacol; 2006 May; 148(1):61-9. PubMed ID: 16520742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist.
    Banno H; Kawazura H; Yutaka T; Sakuma N; Kitamori T; Hosoya J; Kibayashi K; Yamashita H; Umemura K; Nakashima M
    Eur J Pharmacol; 1999 Feb; 367(2-3):275-82. PubMed ID: 10079002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antithrombotic and antiplatelet activities of Korean red ginseng extract.
    Jin YR; Yu JY; Lee JJ; You SH; Chung JH; Noh JY; Im JH; Han XH; Kim TJ; Shin KS; Wee JJ; Yun YP
    Basic Clin Pharmacol Toxicol; 2007 Mar; 100(3):170-5. PubMed ID: 17309520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation on antithrombotic effect of aspirin eugenol ester from the view of platelet aggregation, hemorheology, TXB2/6-keto-PGF1α and blood biochemistry in rat model.
    Ma N; Liu XW; Yang YJ; Shen DS; Zhao XL; Mohamed I; Kong XJ; Li JY
    BMC Vet Res; 2016 Jun; 12(1):108. PubMed ID: 27296110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity.
    Hernandez MR; Tonda R; Pedreño J; Salas E; Arderiu G; Pino M; Serradell M; Escolar G
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):859-65. PubMed ID: 17122671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The inhibitory effect of oxaprozin, a new non-steroidal anti-inflammatory drug, on platelet aggregation].
    Goto J; Muramatsu M; Hosoda K; Otomo S; Aihara H
    Nihon Yakurigaku Zasshi; 1984 May; 83(5):395-400. PubMed ID: 6432657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
    Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
    Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aqueous extracts of Ocimum basilicum L. (sweet basil) decrease platelet aggregation induced by ADP and thrombin in vitro and rats arterio--venous shunt thrombosis in vivo.
    Tohti I; Tursun M; Umar A; Turdi S; Imin H; Moore N
    Thromb Res; 2006; 118(6):733-9. PubMed ID: 16469363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
    Vilahur G; Casaní L; Badimon L
    Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diindolylmethane ameliorates platelet aggregation and thrombosis: In silico, in vitro, and in vivo studies.
    Ramakrishna K; Singh N; Krishnamurthy S
    Eur J Pharmacol; 2022 Mar; 919():174812. PubMed ID: 35151647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.